Meta-analysis of the relation between vitamin D receptor gene BsmI polymorphism and susceptibility to ovarian cancer

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3317-3321

  Zhang, Yan ^a   Tong, Sheng Chun ^a   Guan, Li Hua ^a   Na, Fei ^a   Zhao, Wei ^a   Wei, Li ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Ovarian cancer; Polymorphism; Susceptibility; Vitamin D receptor

Indexed keywords

VITAMIN D RECEPTOR;

ARTICLE; CANCER SUSCEPTIBILITY; CAUCASIAN; CORRELATION ANALYSIS; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; SYSTEMATIC REVIEW; VDR GENE;

EID: 84891486088     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0900-2     Document Type: Article

References (26)

1. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55:3-23.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA. 2008;299:2423-36.
4. Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Int Med. 2012;271:366-78.
5. Musrap N, Diamandis EP. Revisiting the complexity of the ovarian cancer microenvironment - clinical implications for treatment strategies. Mol Cancer Res. 2012;10:1254-64.
6. Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13:946-56.
7. Heitz F, Harter P, Barinoff J, Beutel B, Kannisto P, Grabowski JP. Bevacizumab in the treatment of ovarian cancer. Adv Ther. 2012;29:723-35.
8. Picotto G, Liaudat AC, Bohl L, Tolosa de Talamoni N. Molecular aspects of vitamin D anticancer activity. Cancer Investig. 2012;30:604-14.
9. Wolden-Kirk H, Gysemans C, Verstuyf A, Mathieu C. Extraskeletal effects of vitamin D. Endocrinol Metab Clin North Am. 2012;41:571-94.
10. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev. 2012;33:456-92.
11. Chen L, Davey Smith G, Evans DM, Cox A, Lawlor DA, Donovan J, et al. Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev. 2009;18:2874-81.
12. Byers SW, Rowlands T, Beildeck M, Bong YS. Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Rev Endocr Metab Disord. 2012;13:31-8.
13. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010;376:180-8.
14. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2566-71.
15. Clendenen TV, Arslan AA, Koenig KL, Enquist K, Wirgin I, Agren A, et al. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett. 2008;260:209-15.
16. Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, Cramer D, et al. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res. 2009;69:1885-91.
17. Grant DJ, Hoyo C, Akushevich L, Iversen ES, Whitaker R, Marks J, et al. Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. Gynecol Oncol. 2013;129:173-8.
18. Mostowska A, Sajdak S, Pawlik P, Lianeri M, Jagodzinski PP. Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population. Genet Test Mol Biomarkers. 2013;17:183-7.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
23. Chen Y, Liu W, Sun T, Huang Y, Wang Y, Deb DK, et al. 1,25-Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting microRNA-155-SOCS1 in macrophages. J Immunol. 2013;190:3687-95.
24. 3 through DNA methylation and histone modification. PLoS One. 2013;8:e61423.
25. Gunduz M, Cacina C, Toptas B, Yaylim-Eraltan I, Tekand Y, Isbir T. Association of vitamin D receptor gene polymorphisms with colon cancer. Genet Test Mol Biomarkers. 2012;16:1058-61.
26. Rowland GW, Schwartz GG, John EM, Ingles SA. Protective effects of low calcium intake and low calcium absorption vitamin D receptor genotype in the California collaborative prostate cancer study. Cancer Epidemiol Biomarkers Prev. 2013;22:16-24.